The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (“CHMP”) has ... of its BTK inhibitor, Jaypirca (pirtobrutinib ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...

which generally follows the CHMP's advice, is expected to make a final decision in the next one to two months. Eli Lilly previously won conditional European approval for Jaypirca in adults with ...

(RTTNews) - Eli Lilly and Company (LLY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca, a non-covalent ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...